
US FDA approves Pfizer's maternal RSV vaccine to protect infants
U.S. Food and Drug Administration approved Pfizer's respiratory syncytial virus (RSV) vaccine for use in women during the middle of the third trimester of pregnancy to protect their babies.
The approval allows the vaccine to be given to women 32 to 36 weeks into a pregnancy to prevent lower respiratory tract infection & severe disease in infants until they are 6 months old.